Versant Capital Management’s Astria Therapeutics ATXS Stock Holding History

Versant Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-298	Closed	-$3.9K	–	2784
2025 Q4	$3.9K	Hold	298	–	–	﹤0.01%	2331
2025 Q3	$2.17K	Hold	298	–	–	﹤0.01%	2399
2025 Q2	$1.6K	Buy	+298	New	+$1.45K	﹤0.01%	2422

Versant Capital Management's ATXS Position: Q1 2026 in Review

Versant Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 298 shares — an estimated $3.9K sold.

Versant Capital Management first reported a position in ATXS in Q2 2025 and held it in 3 quarters. The position peaked at $3.9K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Versant Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Versant Capital Management sold 298 Astria Therapeutics shares in Q1 2026, an estimated $3.9K.
Versant Capital Management first reported a position in Astria Therapeutics in Q2 2025 and held it in 3 quarters.
Versant Capital Management's Astria Therapeutics position peaked at $3.9K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Versant Capital Management's 13F filing for Q1 2026, filed 7 Apr 2026.